| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development expenses | 719 | 679 | 1,566* | |
| General and administrative expenses | 661 | 1,279 | 389* | |
| Total operating expenses | 1,380 | 1,958 | 1,955 | |
| Operating loss | -1,380 | -1,958 | -1,955* | |
| Other expense direct listing offering costs | - | 586 | 291* | |
| Net loss and comprehensive loss | -1,380 | -2,544 | -2,246 | |
| Basic EPS | -0.03 | -0.05 | -0.049 | |
| Diluted EPS | -0.03 | -0.05 | -0.049 | |
| Basic Average Shares | 48,278,370 | 47,219,329 | 45,422,581 | |
| Diluted Average Shares | 48,278,370 | 47,219,329 | 45,422,581 | |
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)